Corpus overview


Overview

MeSH Disease

HGNC Genes

SARS-CoV-2 proteins

There are no SARS-CoV-2 protein terms in the subcorpus


Filter

Genes
Diseases
SARS-CoV-2 Proteins
    displaying 1 - 3 records in total 3
    records per page




    Laboratory findings in coronavirus disease 2019 MESHD ( COVID-19 MESHD) patients: a comprehensive systematic review and meta-analysis

    Authors: Mohammad Karimian; Amirreza Jamshidbeigi; Gholamreza Badfar; Milad Azami

    doi:10.1101/2020.06.07.20124602 Date: 2020-06-08 Source: medRxiv

    Background: In early December 2019, the first patient with COVID-19 MESHD pneumonia MESHD was found in Wuhan, Hubei Province, China. Recent studies have suggested the role of primary laboratory tests in addition to clinical symptoms for suspected patients, which play a significant role in the diagnosis of COVID-19 MESHD. Therefore, the present study was conducted to evaluate laboratory findings in COVID-19 MESHD patients. Material and methods: The present meta-analysis was reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines. This protocol is registered with the code CRD42019145410 in PROSPERO International Database. Results: Finally, 52 studies involving 5490 patients with COVID-19 MESHD entered the meta-analysis process. The prevalence of leukopenia MESHD, lymphopenia MESHD, elevated c-reactive protein HGNC ( CRP HGNC), elevated erythrocyte sedimentation rate (ESR), elevated serum amyloid A, elevated ferritin was estimated to be 20.9% (95%CI: 17.9-24.3), 51.6% (95%CI: 44.0-59.1), 63.6% (95%CI: 57.0-69.8), 62.5% (95%CI: 50.1-73.5), 63.6% (95%CI: 57.0-69.8), 62.5% (95%CI: 50.1-73.5), 74.7% (95%CI: 50.0-89.7), and 72.6% (95%CI: 58.1-83.5), respectively. The prevalence of elevated interleukin-6 HGNC was 59.9% (95%CI: 48.2-70.5), CD3 was 68.3% (95%CI: 50.1-82.2), reduced CD4 HGNC was 62.0% (95%CI: 51.1-71.6), reduced CD8 HGNC was 42.7% (95%CI: 32.2-53.9). The prevalence of elevated troponin-I was 20.6% (95%CI: 9.0-40.5), elevated creatine kinase-MB (CKMB) was 14.7% (95%CI: 7.1-28.0), elevated brain natriuretic peptide ( BNP HGNC) was 48.9% (95%CI: 30.4-67.7), elevated blood urea nitrogen was 13.1% (95%CI: 6.6-24.4),, elevated creatinine was 7.2% (95%CI: 4.4-11.8), elevated lactate dehydrogenase (LDH) was 53.1% (95%CI: 43.6-62.4), hyperglycemia MESHD was 41.1% (95% CI: 28.2-55.5), elevated total bilirubin was 48.9% (95%CI: 30.4-67.7), reduced albumin was 54.7% (95%CI: 38.1-70.2), reduced pre-albumin was 49.0% (95%CI: 26.6-71.8), and reduced PT was 53.1% (95% CI: 43.6-62.4), and D-dimer was 44.9% (95%CI: 31.0-59.6). Conclusion This study provides a comprehensive description of laboratory characteristics in patients with COVID-19 MESHD. The results show that lymphopenia MESHD, elevated CRP HGNC, elevated ESR, elevated ferritin, elevated serum amyloid A, elevated BNP HGNC, reduced albumin, reduced pre-albumin, reduced CD3, reduced CD4 HGNC, reduced CD8 HGNC, elevated D-dimer, reduced PT, elevated interleukin-2 HGNC, elevated interleukin-6 HGNC, elevated LDH and hyperglycemia MESHD are the common findings at the time of admission.

    Clinical features and outcomes of 2019 novel coronavirus-infected patients with high plasma BNP HGNC levels

    Authors: youbin liu; Dehui Liu; Huafeng Song; Chunlin chen; Mingfang lv; Xing pei; Zhongwei Hu; Zhihui Qin; Jinglong Li

    doi:10.1101/2020.03.31.20047142 Date: 2020-04-02 Source: medRxiv

    Aims To explore clinical features and outcome of 2019 novel coronavirus(2019-nCoV)-infected patients with high BNP HGNC levels Methods and results Data were collected from patients medical records, and we defined high BNP HGNC according to the plasma BNP HGNC was above > 100 pg/mL. In total,34 patients with corona virus disease MESHD 2019( COVID-19 MESHD)were included in the analysis. Ten patients had high plasma BNP HGNC level. The median age for these patients was 60.5 years (interquartile range, 40-80y), and 6/10 (60%) were men. Underlying comorbidities in some patients were coronary heart disease MESHD (n=2, 20%) ;hypertesion(n=3;30%);, heart failure MESHD (n=1,10%)and diabetes MESHD (n=2, 20%). Six (60%) patients had a history of Wuhan exposure. The most common symptoms at illness onset in patients were fever MESHD (n=7, 70%), cough (n=3, 30%), headache MESHD or fatigue MESHD(n=4,40%);. These patients had higher aspartate aminotransferase( AST HGNC), troponin I, C reactive protein HGNC and lower hemoglobin, and platelet count,compared with patients with normal BNP HGNC, respectively. Compared with patients with normal BNP HGNC, patients with high BNP HGNC were more likely to develop severe pneumonia MESHD, and receive tracheal cannula, invasive mechanical ventilation, continuous renal replacement therapy, extracorporeal membrane oxygenation, and be admitted to the intensive care unit. One patient with high BNP HGNC died during the study.

    Lactate dehydrogenase, a Risk Factor of Severe COVID-19 MESHD Patients

    Authors: Yi Han; Haidong Zhang; Sucheng Mu; Wei Wei; Chaoyuan Jin; Yuan Xue; Chaoyang Tong; Yunfei Zha; Zhenju Song; Guorong Gu

    doi:10.1101/2020.03.24.20040162 Date: 2020-03-27 Source: medRxiv

    BACKGROUND The World Health Organization (WHO) has recently declared coronavirus disease 2019 MESHD ( COVID-19 MESHD) a public health emergency of global concern. Updated analysis of cases might help identify the characteristic and risk factors of the illness severity. METHODS We extracted data regarding 47 patients with confirmed COVID-19 MESHD from Renmin Hospital of Wuhan University between February 1 and February 18, 2020. The degree of severity of COVID-19 MESHD patients (severe vs. non-severe) was defined at the time of admission according to American Thoracic Society (ATS) guidelines for community-acquired pneumonia MESHD (CAP). RESULTS The median age was 64.91 years, 26 cases (55.31%) were male of which, and 70.83% were severe cases. Severe patients had higher APACHE II (9.92 vs 4.74) and SOFA (3.0 vs 1.0) scores on admission, as well as the higher PSI (86.13 vs 61.39), Curb-65 (1.14 vs 0.48) and CT semiquantitative scores (5.0 vs 2.0) when compared with non-severe patients. Among all univariable parameters, APACHE II, SOFA, lymphocytes, CRP HGNC, LDH, AST HGNC, cTnI HGNC, BNP HGNC, et al were significantly independent risk factors of COVID-19 MESHD severity. Among which, LDH was most positively related both with APACHE II (R = 0.682) and SOFA (R = 0.790) scores, as well as PSI (R = 0.465) and CT (R = 0.837) scores. To assess the diagnostic value of these selected parameters, LDH (0.9727) had maximum sensitivity (100.00%) and specificity (86.67%), with the cutoff value of 283. As a protective factor, lymphocyte counts less than 1.045 x 109 /L showed a good accuracy for identification of severe patients with AUC = 0.9845 (95%CI 0.959-1.01), the maximum specificity (91.30%) and sensitivity (95.24%). In addition, LDH was positively correlated with CRP HGNC, AST HGNC, BNP HGNC and cTnI HGNC, while negatively correlated with lymphocyte cells and its subsets, including CD3+, CD4+ and CD8+ T cells (P < 0.01). CONCLUSIONS This study showed that LDH coule be identified as a powerful predictive factor for early recognition of lung injury MESHD and severe COVID-19 MESHD cases. And importantly, lymphocyte counts, especially CD3+, CD4+, and CD8+ T cells in the peripheral blood of COVID-19 MESHD patients, which was relevant with serum LDH, were also dynamically correlated with the severity of the disease. FUNDING Key Project of Shanghai Municipal Health Bureau (2016ZB0202)

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
HGNC Genes
SARS-CoV-2 Proteins


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.